La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aileron Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aileron Therapeutics..

Aileron Therapeutics (NASDAQ:ALRN) Azioni, Catena delle Opzioni

Aileron Therapeutics

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics Inc

WIIM

ALRN

Aileron Therapeutics shares are trading lower. The company reported Q3 financial results.

Earnings

Earnings Beats

News

Aileron Therapeutics Q3 EPS $(0.27) Beats $(0.41) Estimate

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase&nbsp;1b&nbsp;trial of safety and tolerability of inhaled LTI-03 for idiopathic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41934818/aileron-therapeutics-announces-positive-topline-data-from-cohort-2-of-the-phase-1b-clinical-trial-" rel="noreferrer noopener">pulmonary fibrosis (IPF)</a>.
LTI-03 is a novel, Caveolin-1-related peptide that modulates profibrotic activity and sustains critical alveolar epithelial cells.
Following inhaled administration of high dose LTI-03 (5 mg BID), a positive trend was observed in seven out of eight biomarkers, with evidence of reduced expression among profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from four biomarkers that were statistically significant in the combined data set of Cohort 1 and Cohort 2, and data from five biomarkers that showed dose dependence relative to the data from those biomarkers in Cohort 1.
Overall, the collective findings from this Phase&nbsp;1b trial provide the company with strong confidence that LTI-03 has the potential to improve lung function and reverse the course of IPF.
Surfactant protein D (SPD), an indicator of epithelial cell health that is significantly linked to a decline in lung function, decreased by 5% in Cohort 2 at 14 days of treatment, while the current standard of care for IPF reduced SPD by 4% at 12-weeks in precedent trials.
LTI-03 did not induce inflammation in peripheral blood mononuclear cells (PBMCs) in either Cohort, measured by pAKT, a safety marker for inflammation in this trial.
LTI-03 was generally well-tolerated, and there were no drug-related adverse events that resulted in a discontinuation of the trial.
&#8220;I am delighted with the Cohort 2 data as it confirms previous results obtained with LTI-03 in cell experiments, animal studies and ex-vivo studies employing human IPF high precision cut lung slices. In these studies, the evaluated biomarkers were found to be downregulated by LTI-03. These observations have now been reproduced in IPF patients upon inhalative application of LTI-03 vs placebo,&#8221; said Andreas Gunther, Head of the Center for Interstitial and Rare Lung Diseases of the Justus Liebig University in Germany. 
&#8220;Moreover, the profile of the statistically significant changes in the biomarkers in response to LTI-03 treatment also suggests that LTI-03 may not only act on fibroblasts, but also on epithelial cells, which would represent a novel therapeutic principle in the IPF treatment landscape.&#8221;
Price Action: ALRN stock is trading 5.48% lower at $3.62 at last check Wednesday. During the premarket session, the stock reached at $4.48.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/mid-cap/24/11/41944479/kyndryl-dell-nvidia-join-forces-to-launch-ai-private-cloud-for-japanese-enterprises" target="_blank" rel="noreferrer noopener">Kyndryl, Dell, Nvidia Join Forces To Launch AI Private Cloud For Japanese Enterprises</a></li>
</ul>

Biotech

Health Care

Movers

General

Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis

Aileron Therapeutics shares are trading higher after the company announced topline data from cohort 2 of its Phase 1b clinical trial of LTI-03 in IPF.

Aileron Therapeutics Announces Topline Data From Cohort 2 Of Phase 1b Clinical Trial Of LTI-03 In IPF; Says High-Dose LTI-03 Reduced Expression Of Multiple Profibrotic Proteins In Both Pathological Basal-like Cells And Fibroblasts And Decreased The Expression Of A Biomarker Indicative Of Epithelial Health And Lung Function Decline

Under the terms of the option agreement, Advancium paid Aileron a non-refundable fee for the exclusive option to acquire ALRN-6924 and related assets. If Advancium exercises its option, Aileron will receive an exercise payment with potential for additional development, regulatory and commercial milestone payments and sales royalties.
&nbsp;
During the option period, Advancium intends to evaluate ALRN-6924 as a potential therapy for retinoblastoma (RB), a rare but devastating cancer of the eye, with around 300 cases diagnosed in the United States and 9,000 cases worldwide each year, nearly all in children [1]. With early intervention the disease is rarely fatal; however, non-selective chemotherapy with its attendant side effects remains the usual treatment strategy, and removal of the affected eye(s) is a frequent outcome. In contrast to chemotherapy, ALRN-6924 selectively targets MDM2 and MDMX, the endogenous inhibitors of the regulatory protein p53, to activate p53-mediated tumor suppression in cancer cells [2]. Previous studies have implicated the MDMX protein as a key driver of RB tumorigenesis [3], and ALRN-6924 is the first and only clinical-stage drug that acts on MDMX. ALRN-6924 has previously been studied in preclinical models of RB, where it showed potent, on-mechanism anti-proliferative activity in RB cell lines and was found to be highly soluble and compatible with intraocular injection [4].

Contracts

Aileron Therapeutics And Advancium Health Network Announced An Exclusive Option Agreement For The Acquisition Of ALRN-6924, Developed By Aileron Prior To Its 2023 Merger With Lung Therapeutics

<ul>
<li>First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase&nbsp;1b&nbsp;clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect</li>
<li>Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term</li>
</ul>

Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the completion of enrollment in Cohort 2 of the ongoing Phase 1b clinical trial of LTI-03 in IPF patients.
&nbsp;
The last patient was enrolled in mid-September, with a total of 24 patients enrolled in the trial. Eligible patients are randomly assigned (3:1) to receive either inhaled LTI-03 or placebo. The primary objective of the trial is to evaluate the safety and tolerability of LTI-03 in patients with IPF after treatment for 14 consecutive days, with measurement of multiple protein biomarkers as exploratory endpoints.
"We are pleased to have completed enrollment in the high-dose cohort of our Phase 1b clinical trial and grateful to all participating patients and investigators," said Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron. "Following the positive trend observed in the low-dose cohort, we are excited to assess the safety, tolerability and biomarkers of 5 mg twice daily of inhaled LTI-03 and expect to report topline data in the near term."
In May 2024, the Company <a href="https://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-announces-positive-data-cohort-1-phase-1b">announced positive data</a> from Cohort 1 evaluating low-dose LTI-03 (2.5 mg BID). Following inhaled administration of low-dose LTI-03 in 12 patients, a positive trend was observed in seven out of eight biomarkers with evidence of reduced expression among multiple profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from three biomarkers that was statistically significant, reinforcing the potential of LTI-03 to improve lung function and reverse the course of IPF.
About the Phase 1 Clinical Trial of LTI-03
The Phase 1b clinical trial of LTI-03 is a randomized, double-blind, placebo controlled, multi-center, dose escalation trial in patients recently diagnosed with IPF that have not received prior treatment with anti-fibrotic agents for at least two months (<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05954988">NCT05954988</a>). Eligible patients are randomly assigned (3:1) to receive one of two doses of inhaled LTI-03 or placebo. The primary objective of the trial is to investigate the safety and tolerability of LTI-03 in patients with IPF after treatment for 14 consecutive days, with measurement of multiple protein biomarkers as exploratory endpoints.

Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon

Aileron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.39) per share from the same period last year.

Earnings Misses

Aileron Therapeutics Q2 2024 GAAP EPS $(0.45) Misses $(0.42) Estimate; Cash Position $21.9M

Offerings

Aileron Therapeutics Got Into Equity Distribution Agreement, May Offer & Sell Shares Of Our Common Stock From Time To Time Of Up To $50M

Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap&#xAE;&nbsp;Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

Aileron Therapeutics Included In The Russell Microcap Index

Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.14) by 514.29 percent.

Aileron Therapeutics Q1 2024 GAAP EPS $(0.86) Misses $(0.14) Estimate

Aileron Therapeutics shares are trading lower after the company announced the pricing of  an underwritten registered direct offering of 4,273,505 shares and accompanying warrants at a combined offering price of $4.68.

Aileron Therapeutics Prices 4,273,505 Offering Of Shares And Accompanying Warrants At Combined Offering Price Of $4.68

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect &nbsp;
Positive trend was observed in seven of eight IPF biomarkers evaluated
Low-dose LTI-03 was well-tolerated, with no safety signal observed
Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter of 2024
Company to host conference call on Wednesday, May 1st at 9:00 am ET

Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock moved upwards by 53.88% to $6.54. The company's market cap stands at $111.0 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 45.48% to $0.52. The company's market cap stands at $250.2 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 40.75% to $0.05. The company's market cap stands at $6.4 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares moved upwards by 33.19% to $0.28. The company's market cap stands at $2.5 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares moved upwards by 25.62% to $6.03. The market value of their outstanding shares is at $15.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) stock decreased by 27.0% to $0.51 during Thursday's regular session. The company's market cap stands at $38.4 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock declined by 26.35% to $5.34. The company's market cap stands at $29.2 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock fell 25.12% to $3.13. The market value of their outstanding shares is at $29.9 million. </li>
<li>Genetic Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) stock fell 23.74% to $2.41. The market value of their outstanding shares is at $9.2 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock fell 20.39% to $0.29. The market value of their outstanding shares is at $13.8 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock decreased by 20.34% to $1.45. The market value of their outstanding shares is at $3.9 million. The company's, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTC

BPTH

GENE

INVO

ISPC

NRXP

OTRK

SINT

12 Health Care Stocks Moving In Thursday's Intraday Session

Aileron Therapeutics shares are trading higher after Ladenburg Thalmann maintained a Buy rating on the stock and raised its price target from $9 to $19. Also, the company filed U.S. Patent Application number 20240124518 titled "Methods For Preparing Purified Polypeptide Compositions"

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240124518" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240124518">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240124518</a>

Aileron Therapeutics Filed U.S. Patent Application #20240124518: Methods For Preparing Purified Polypeptide Compositions

Shares of Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) fell sharply during Thursday's session despite <a href="https://www.benzinga.com/news/earnings/24/04/38302237/las-vegas-sands-reports-better-than-expected-q1-results">better-than-expected first-quarter results.</a>
The company reported quarterly adjusted earnings of 75 cents per share which beat the analyst consensus estimate of 62 cents and represented a 167.86% increase from the same period last year. Quarterly sales clocked in at $2.96 billion which beat the analyst consensus estimate of $2.94 billion and is a 39.58% increase over sales of $2.12 billion from the same quarter last year, according to data from Benzinga Pro.
Las Vegas Sands shares dipped 6.8% to $46.81 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h2 class="wp-block-heading">Gainers</h2>
<ul>
<li>AGBA Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGBA#NASDAQ">AGBA</a>) shares jumped 148% to $0.9898 after the company announced it entered into a definitive merger agreement with Triller.</li>
<li> Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) jumped 106% to $1.0012 after gaining around 8% on Wednesday.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) gained 77.7% to $5.74 after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.</li>
</ul>
<ul>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) rose 51% to $0.0560.</li>
<li>23andMe Holding Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) gained 44% to $0.5035 after CEO Anne Wojcicki said she is considering a proposal to take the company private.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) gained 42.5% to $2.75. Expion360 announced &#8216;substantial&#8217; preorders of its Group 27 and GC2 now featuring Vertical Heat Conduction&#x2122; Heating Technology.</li>
<li>Vertex Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTNR#NASDAQ">VTNR</a>) rose 31% to $1.2901.</li>
<li>Aileron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) jumped 29.4% to $5.50. Ladenburg Thalmann analyst Aydin Huseynov maintained Aileron Therapeutics with a Buy and raised the price target from $9 to $19.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) gained 26.5% to $2.8350.</li>
<li>TH International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THCH#NASDAQ">THCH</a>) shares surged 26.4% to $1.3190 after the company reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Tiziana Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) gained 20.1% to $0.6160. Tiziana Life Sciences announced new quantitative PET imaging data on Foralumab at Meeting of American Academy of Neurology.</li>
<li>Smith Micro Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) climbed 18.7% to $2.3150.</li>
<li>Warrantee Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRNT#NASDAQ">WRNT</a>) rose 15.8% to $0.3745.</li>
<li>Badger Meter, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) gained 11.8% to $171.06 after the company reported better-than-expected first-quarter results.</li>
<li>Genuine Parts Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NASDAQ">GPC</a>) rose 11.1% to $160.05 after the company reported a first-quarter EPS beat and raised its FY24 guidance.</li>
<li>Barnes Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) gained 8.8% to $36.31. DA Davidson analyst Matt Summerville upgraded Barnes from Neutral to Buy and raised the price target from $35 to $45.</li>
<li>Apogee Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) climbed 8.1% to $60.42 following upbeat quarterly earnings.</li>
</ul>
<h2 class="wp-block-heading">Losers</h2>
<ul>
<li>iLearningEngines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares dipped 29.8% to $7.02.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) fell 28.4% to $0.2574. SuperCom announced pricing of $2.9 million registered direct offering.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) shares fell 28.6% to $4.75. Edible Garden recently reported a year-over-year increase in preliminary first-quarter revenues.</li>
<li>Lithium Americas Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAC#NYSE">LAC</a>) fell 28% to $4.7750 after the company priced a $275 million public offering.</li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) fell 27.5% to $4.1920.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) fell 27.1% to $3.04. NRx Pharmaceuticals announced pricing of $2 million underwritten public offering of common stock at a public offering price of $3.30 per share.</li>
<li>Kartoon Studios Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOON#NASDAQ">TOON</a>) fell 25.3% to $1.1050 as the company announced pricing of up to $7 million registered direct offering of common stock.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) declined 24.4% to $1.3750. INVO BioScience recently reported a year-over-year increase in fourth-quarter revenue results.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) fell 24.4% to $0.2994. Windtree Therapeutics announced a 1-for-18 reverse stock split effective April 22.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) fell 24.1% to $3.17. NRx Pharmaceuticals announced pricing of $2 million underwritten public offering of common stock at a public offering price of $3.30 per share.</li>
<li>WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) fell 24.2% to $7.01.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) dipped 11.2% to $8.53. SolarMax Technology recently reported fiscal year 2023 results.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) fell 10.5% to $6.79. Ocular Therapeutix reported topline Phase 1 data for AXPAXLI in diabetic retinopathy.</li>
<li>Primerica, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) fell 8.6% to $193.38 following a report from The Bear Cave.</li>
<li> Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) shares declined 6.7% to $34.17 as the company posted weaker-than-expected results for its first quarter.</li>
<li> Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) fell 6.2% to $223.07 after the company reported worse-than-expected first-quarter sales results and issued adjusted guidance below estimates.</li>
<li> Snap-on Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) shares fell 5.5% to $267.96 following weak quarterly sales.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38312420/how-to-earn-500-a-month-from-ford-stock-ahead-of-q1-earnings-report">How To Earn $500 A Month From Ford Stock Ahead Of Q1 Earnings Report</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="996" height="664" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18113438/Image14-1.jpg" alt="" class="wp-image-298250" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18113438/Image14-1.jpg 996w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18113438/Image14-1-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18113438/Image14-1-768x512.jpg 768w" sizes="(max-width: 996px) 100vw, 996px" /></figure>

Markets

AGBA

AILE

APOG

BENF

EDBL

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

OCUL

SMSI

SMXT

SPCB

THCH

TIRX

TLSA

TOON

VTNR

WINT

WISA

WRNT

XPON

Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M

Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Aileron Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/alrn-stock-quote/">ALRN</a>) just reported results for the first quarter of 2024.<ul><li>Aileron Therapeutics reported earnings per share of -86 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/alrn-stock-earnings-aileron-therapeutics-for-q1-of-2024/">ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024

An update from Aileron Therapeutics Inc (ALRN) is now available. Aileron Therapeutics, Inc. has appointed Timothy M. Cunningham as the interim chie...

Aileron Therapeutics Announces New Interim CFO Appointment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Aileron Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/alrn-stock-quote/">ALRN</a>) just reported results for the second quarter of 2024.<ul><li>Aileron Therapeutics reported earnings per share of -45 cents. This was below the analyst estimate for EPS of -42 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/alrn-stock-earnings-aileron-therapeutics-for-q2-of-2024/">ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024

Aileron Therapeutics GAAP EPS of -$0.45

Aileron Therapeutics (ALRN) and Advancium Health Network, a public charity founded by Deerfield Management and the Deerfield Foundation to meet the...

Aileron Therapeutics' ALRN-6924 to be acquired by Advancium Health Network

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability of ...

Aileron reports results from Cohort 2 of its Phase 1b clinical trial of LTI-03

Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02

Aileron Therapeutics ( ($ALRN) ) has released its Q3 earnings. Here is a breakdown of the information Aileron Therapeutics presented to its investo...

Aileron Therapeutics Reports Q3 2024 Financial Results

Press Releases

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics to Present at the 8th Annual IPF Summit

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Comments

Aileron Therapeutics

Aileron Therapeutics (ALRN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO